Literature DB >> 17671725

Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.

Toru Takano1, Yasuhiro Ito, Fumio Matsuzuka, Akihiro Miya, Kaoru Kobayashi, Hiroshi Yoshida, Akira Miyauchi.   

Abstract

Anaplastic thyroid carcinomas (ATC) are undifferentiated tumors that show rapid progression and dissemination. The recent increase in knowledge about cancer stem cells has attracted marked interest in ATC, since these lesions are suggested to be closely related to thyroid stem cells (TSCs). Due to the rarity of ATCs, however, the gene expression patterns that characterize these lesions have not been fully clarified. Using real-time quantitative reverse transcription-polymerase chain reaction, we measured the mRNA expression levels of three representative genes, telomerase reverse transcriptase (hTERT), thyroglobulin and thyroid transcription factor 1 (TTF-1) in twelve frozen tissue samples of ATC and six cell lines derived from ATCs. All twelve ATC specimens and six ATC cell lines showed an increased expression of hTERT mRNA but the expression levels of hTERT mRNA did not show a clear difference between ATCs and other thyroid tumors. The mean expression level of thyroglobulin mRNA in the ATCs and ATC cell lines was <10(2) times higher than that in the differentiated thyroid carcinomas. All twelve ATCs showed a loss of TTF-1 mRNA expression, but two cell lines, TCO-1 and 8505C, expressed TTF-1 mRNA. In conclusion, ATC tissues and cell lines were characterized by the expression of hTERT and a loss of thyroglobulin expression, concordant with the general recognition. However, the loss of TTF-1 expression can not characterize ATC cells, as some ATC cell lines expressed TTF-1 mRNA abundantly. This information could contribute to clarifying the nature of ATCs and could be useful in detecting TSCs, which have not yet been identified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671725

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

2.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

3.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

4.  Transcriptional activity of the 5'-flanking region of the thyroid transcription factor-1 gene in human thyroid cell lines.

Authors:  Hiroya Yamada; Toru Takano; Fumio Matsuzuka; Mikio Watanabe; Akira Miyauchi; Yoshinori Iwatani
Journal:  Genet Mol Biol       Date:  2011-03-01       Impact factor: 1.771

5.  Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.

Authors:  Paula Soares; Jorge Lima; Ana Preto; Patricia Castro; João Vinagre; Ricardo Celestino; Joana P Couto; Hugo Prazeres; Catarina Eloy; Valdemar Máximo; M Sobrinho-Simões
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

6.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

7.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.